Electron transfer flavoprotein, deficiency of

Electron Transfer Flavoprotein Deficiency (ETFD) is a rare genetic disorder affecting the mitochondrial respiratory chain. This condition disrupts the normal function of mitochondria, which are responsible for creating energy in cells. ETFD is part of a group of disorders known as mitochondrial fatty acid oxidation disorders. The disease is characterized by a wide range of clinical manifestations, from mild to severe, including hypoglycemia, muscle weakness, and cardiomyopathy.

Etiology

ETFD is caused by mutations in either the ETFA or ETFB gene, which encode the alpha and beta subunits of the electron transfer flavoprotein (ETF) complex, respectively. This complex plays a crucial role in the mitochondrial electron transport chain, facilitating the transfer of electrons from various substrates to the ubiquinone pool. Mutations in these genes lead to a deficiency in ETF activity, resulting in impaired energy production, especially during periods of fasting or illness.

Pathophysiology

The primary function of the electron transfer flavoprotein is to serve as an electron acceptor for several dehydrogenases, particularly those involved in the oxidation of fatty acids and the metabolism of some amino acids. In ETFD, the defective transfer of electrons leads to an accumulation of fatty acids and their derivatives, which can be toxic to cells. This accumulation, particularly in organs with high metabolic rates such as the liver, heart, and muscles, results in the clinical manifestations of the disease.

Clinical Manifestations

The symptoms of ETFD can vary widely among affected individuals. Common clinical features include:

• Hypoglycemia (low blood sugar)
• Muscle weakness
• Exercise intolerance
• Cardiomyopathy (disease of the heart muscle)
• Liver dysfunction
• Neurological abnormalities, including developmental delay and seizures in severe cases

Diagnosis

Diagnosis of ETFD involves a combination of clinical evaluation, biochemical tests, and genetic testing. Biochemical tests may show abnormalities in plasma acylcarnitine profile, indicative of impaired fatty acid oxidation. Molecular genetic testing can confirm the diagnosis by identifying mutations in the ETFA or ETFB genes.

Treatment

There is no cure for ETFD, and treatment is primarily supportive and symptomatic. Management strategies may include:

• Avoidance of fasting to prevent hypoglycemia
• Dietary management with a low-fat diet and medium-chain triglyceride (MCT) supplementation
• Carnitine supplementation to facilitate the removal of accumulated fatty acids
• Management of cardiomyopathy and liver dysfunction as needed

Prognosis

The prognosis for individuals with ETFD varies depending on the severity of the disease and the effectiveness of management strategies. Early diagnosis and intervention can improve the quality of life and reduce the risk of severe complications.

This metabolic pathology related article is a stub. You can help WikiMD by expanding it.